NovoLog® has faster absorption, faster onset of action and shorter duration of action than regular human insulin. The quick onset of blood sugar lowering after injection of NovoLog® allows people with diabetes to inject themselves immediately before eating, offering flexibility to patients. Traditional regular human insulin requires people to inject their insulin dosage 30 minutes before eating.
"NovoLog® will add the option of another fine Novo Nordisk product to the treatment choice for Americans with diabetes, and will complement our range of therapeutics and medical devices such as NovoPen®3," said Bill Poole, president, Novo Nordisk Pharmaceuticals, Inc.
NovoLog® is sold as NovoRapid® outside the US. Novo Nordisk received marketing approval for NovoRapid® from the European Union last year, and it is now available in several European countries, including the United Kingdom and Germany. Other diabetes products currently in development include premixed and long-acting insulin analogues.
Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of enzymes for industrial use. Headquartered in Denmark, Novo Nordisk employs approximately 15,200 people in 68 countries and markets its products in 179 countries. Its B shares are listed on the stock exchanges in Copenhagen and London. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO". A demerger of Novo Nordisk with the intention to spin off the Enzyme Business into a separately listed company is expected to take place around the turn of the year 2000/2001. For further company information, visit Novo Nordisk on the World Wide Web at www.novo.dk.
For further information please contact:
Communications & Design
Media:
Søren Møller Christensen
Phone: (direct) (+45) 4442 1207
Søren Møller Christensen
Phone: (direct) (+45) 4442 1207
Media in North America:
Susan Toth Jackson
Phone: (+1) 212-867-0123
Susan Toth Jackson
Phone: (+1) 212-867-0123
Investors:
Rasmus Holm-Jørgensen
Phone (direct): (+45) 4442 2983
Rasmus Holm-Jørgensen
Phone (direct): (+45) 4442 2983
Investors in North America:
Peter Lundby Hansen
Phone: (+1) 212-878-9607
Peter Lundby Hansen
Phone: (+1) 212-878-9607